More good news...it is not XONON, but good nonetheless.
Troy
MOUNTAIN VIEW, Calif.--(BW HealthWire)--Sept. 15, 1999-- Catalytica Pharmaceuticals, Inc., a subsidiary of Catalytica, Inc. (Nasdaq:CTAL), announced today that it has signed a preferred supply agreement with Shire Pharmaceuticals Group plc (LSE:SHP.L) (Nasdaq:SHPGY). Under the terms of the five-year agreement, with provisions for a five-year renewal, Catalytica Pharmaceuticals will manufacture several Shire products at its Greenville, North Carolina facility. Additionally, the agreement covers certain development and reformulation of products and allows for the addition of new Shire products.
According to Dr. Gabriel Cipau, President and CEO of Catalytica Pharmaceuticals, "We are very pleased to form this partnership with Shire. This agreement establishes a long-term relationship and allows both parties to benefit from our collective strengths. Catalytica has unique capabilities to handle every phase of chemical process and formulation development as well as complete facilities for product manufacturing. We believe this comprehensive capability can increase efficiencies in the production process and offer Shire the ability to better manage the outsourcing of products."
Commenting on the agreement, Rolf Stahel, Chief Executive of Shire, said: "Shire is very pleased to enter into this agreement with Catalytica. The consolidation of manufacturing for certain products to one site, which can handle such diverse requirements as manufacturing development work and the handling of a broad range of products, is an obvious advantage for Shire."
Shire Pharmaceuticals Group plc is an emerging pharmaceutical company focused primarily on two therapeutic areas; central nervous system disorders and metabolic/ bone diseases, with sales, marketing and R&D operations in the U.S. and the UK.
Remainder of article with general BS omited... |
